References

2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias

10.1016/j.atherosclerosis.2025.120479 · 2025 · External reference

Low‐density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel

10.1093/eurheartj/ehx144 · 2017 · External reference

Antiseizure medications and cardiovascular events in older people with epilepsy in the Canadian longitudinal study on aging

10.1001/jamaneurol.2024.3210 · 2024 · External reference

Cardiovascular disease risk, awareness, and treatment in people with epilepsy

10.1016/j.yebeh.2021.107878 · 2021 · External reference

Enzyme induction with antiepileptic drugs: Cause for concern?

10.1111/j.1528-1167.2012.03671.x · 2013 · External reference

Antiepileptic drug use for treatment of epilepsy and dyslipidemia: Systematic review

10.1016/j.eplepsyres.2015.03.002 · 2015 · External reference

The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis

10.1111/epi.17822 · 2024 · External reference

Cardiovascular effects of antiseizure medications for epilepsy

10.1007/s40263-025-01163-x · 2025 · External reference

Evaluation of effect of antiepileptic drugs on serum lipid profile among young adults with epilepsy in a tertiary Care Hospital in Pondicherry

2014 · External reference

Preliminary report on effects of oxcarbazepine‐treatment on serum lipid levels in children

10.1111/j.1468-1331.2006.01535.x · 2006 · External reference

Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial‐onset seizures: Impact of concomitant statins and enzyme‐inducing antiepileptic drugs

10.1016/j.eplepsyres.2018.02.001 · 2018 · External reference

Cenobamate beyond epilepsy: Exploring associations with vascular risk factors through serological markers

10.1016/j.yebeh.2026.110890 · 2026 · External reference

Antiseizure medications and their differing effects on cardiovascular risk

10.1016/j.ebr.2025.100746 · 2025 · External reference

Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

10.1016/j.clpt.2006.09.003 · 2006 · External reference

Unresolved reference

External reference

Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers

10.1111/j.1528-1167.2011.03118.x · 2011 · External reference

Unresolved reference

External reference

Identification of the rate‐determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study

10.1038/clpt.2011.142 · 2011 · External reference

Cytochrome P450 3A induction predicts P‐glycoprotein induction; part 1: Establishing induction relationships using ascending dose rifampin

10.1002/cpt.1073 · 2018 · External reference

Cytochrome P450 3A induction predicts P‐glycoprotein induction; part 2: Prediction of decreased substrate exposure after rifabutin or carbamazepine

10.1002/cpt.1072 · 2018 · External reference

Induction of cytochrome P450 2C9 and P‐glycoprotein activity by antiseizure medications: A systematic review and network meta‐analysis

10.1002/epd2.70232 · 2026 · External reference

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug‐drug interaction studies

10.1111/cts.13357 · 2022 · External reference

A case to support the continued use of rifampin in clinical drug‐drug interaction studies

10.1002/cpt.3256 · 2024 · External reference

The PRISMA extension statement for reporting of systematic reviews incorporating network meta‐analyses of health care interventions: Checklist and explanations

10.7326/m14-2385 · 2015 · External reference

PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews

10.1136/bmj.n160 · 2021 · External reference

Rayyan–A web and mobile app for systematic reviews

10.1186/s13643-016-0384-4 · 2016 · External reference

Reporting guidelines for clinical pharmacokinetic studies: The ClinPK statement

10.1007/s40262-015-0236-8 · 2015 · External reference

10.1002/epd2.70373

10.1002/epd2.70373 · External reference

NMAstudio 2.0: An interactive tool for network meta‐analysis to enhance understanding, interpretation, and communication of the findings

2026 · External reference

Disease‐drug‐drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis

10.1038/clpt.2011.35 · 2011 · External reference

Lactonization is the critical first step in the disposition of the 3‐hydroxy‐3‐methylglutaryl‐CoA reductase inhibitor atorvastatin

10.1016/s0090-9556(24)15086-6 · 2000 · External reference

Unresolved reference

External reference

Statins for the prevention of post‐stroke seizure and epilepsy development: A systematic review and meta‐analysis

10.1016/j.jstrokecerebrovasdis.2021.106024 · 2021 · External reference

Statin treatment reduces the risk of poststroke seizures

10.1212/wnl.0000000000001814 · 2015 · External reference

Effects of double‐dose statin therapy for the prevention of post‐stroke epilepsy: A prospective clinical study

10.1016/j.seizure.2021.04.010 · 2021 · External reference

Efficacy and safety of antiseizure medication in post‐stroke epilepsy

10.1016/j.seizure.2022.07.003 · 2022 · External reference

Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli

10.1111/ane.13323 · 2020 · External reference

Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post‐stroke epilepsy: A proof‐of‐concept, phase 2a, randomised, double‐blind, placebo‐controlled antiepileptogenesis trial

10.1016/s1474-4422(25)00491-0 · 2026 · External reference

Safety, tolerability and efficacy of Eslicarbazepine acetate as adjunctive therapy in patients aged ≥ 65 years with focal seizures

10.1007/s40266-018-0602-y · 2018 · External reference

Efficacy and safety of eslicarbazepine‐acetate in elderly patients with focal epilepsy: Case series

10.1016/j.seizure.2017.04.003 · 2017 · External reference

The level is in the details: Why differences between direct‐acting oral anticoagulants should be considered in the treatment of patients with epilepsy

10.1111/epi.18144 · 2024 · External reference

Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women

10.1016/j.eplepsyres.2013.02.020 · 2013 · External reference

Association between antiseizure drug monotherapy and mortality for patients with poststroke epilepsy

10.1001/jamaneurol.2021.4584 · 2022 · External reference

Bempedoic acid, the first‐in‐class Oral ATP citrate lyase inhibitor with Hypocholesterolemic activity: Clinical pharmacology and drug‐drug interactions

10.3390/pharmaceutics16111371 · 2024 · External reference

Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions

10.2165/00003088-200544050-00002 · 2005 · External reference

Coordinated regulation of hepatic phase I and II drug‐metabolizing genes and transporters using AhR‐, CAR‐, PXR‐, PPARα‐, and Nrf2‐null mice

10.1124/dmd.112.045112 · 2012 · External reference

Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine

10.1016/j.clpt.2006.08.013 · 2006 · External reference

A mechanistic approach to antiepileptic drug interactions

10.1345/aph.17332 · 1998 · External reference

Unresolved reference

External reference

Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide 1B clinical probe than rosuvastatin

10.1111/bcp.12377 · 2014 · External reference